AKEBIA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9892 USD | +6.98% |
|
+5.23% | -20.23% |
| 06-24 | Akebia Therapeutics Names Erik Ostrowski CFO, CBO | MT |
| 06-24 | Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer | CI |
| Sales 2024 * | 173M 236M | Sales 2025 * | 159M 218M | Capitalization | 194M 265M |
|---|---|---|---|---|---|
| Net income 2024 * | -64M -87.64M | Net income 2025 * | -73M -99.97M | EV / Sales 2024 * | 1.12 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.22 x |
| P/E ratio 2024 * |
-3.56
x | P/E ratio 2025 * |
-2.83
x | Employees | 167 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akebia Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +6.98% | ||
| 1 week | +5.23% | ||
| Current month | -11.68% | ||
| 1 month | -7.55% | ||
| 3 months | -55.84% | ||
| 6 months | -17.57% | ||
| Current year | -20.23% |
1 week
0.80
1.03
1 month
0.801.20
Current year
0.802.48
1 year
0.782.48
3 years
0.244.33
5 years
0.2413.71
10 years
0.2429.67
| Managers | Title | Age | Since |
|---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 22-03-31 |
Michel Dahan
COO | Chief Operating Officer | 45 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 18-12-11 |
Adrian Adams
CHM | Chairman | 73 | 18-12-11 |
LeAnne Zumwalt
BRD | Director/Board Member | 65 | 21-02-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-27 | 0.9892 | +6.98% | 7 756 180 |
| 24-06-26 | 0.9247 | +7.94% | 5,988,886 |
| 24-06-25 | 0.8567 | -5.20% | 3,809,001 |
| 24-06-24 | 0.9037 | -0.69% | 4,017,098 |
| 24-06-21 | 0.91 | -3.19% | 3,683,505 |
Delayed Quote Nasdaq, June 27, 2024 at 04:00 pm
More quotes
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Companyâs portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9247
USD
Average target price
5
USD
Spread / Average Target
+440.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.23% | 194M | |
| +16.13% | 122B | |
| +19.65% | 115B | |
| +21.22% | 26.64B | |
| -23.84% | 19.91B | |
| -17.47% | 16.32B | |
| -45.95% | 15.52B | |
| -19.28% | 15.49B | |
| +63.81% | 14.83B | |
| +1.94% | 13.67B |
- Stock Market
- Equities
- AKBA Stock
